Personalized dna neoantigen vaccine (gnospv02) in combination with plasmid il-12 and pembrolizumab as second-line (2l) treatment for advanced hepatocellular carcinoma (hcc)
JOURNAL FOR IMMUNOTHERAPY OF CANCER(2022)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要